Trial Profile
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions; Expanded access
- Sponsors Novartis; Novartis Pharmaceuticals
- 04 Dec 2018 Results (Dec 29, 2017) consolidated findings from the Expanded Treatment Protocol study at week 96 data cut off, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 04 Dec 2018 Algeria, Argentina, Brazil, Colombia, Croatia, Estonia, Hungary, India, Indonesia, Israel, Italy, Jordan, Lebanon, Morocco, Netherlands, Poland, Romania, Saudi Arabia, Slovakia, Slovenia, South Africa, South Korea, Spain, Taiwan, Tunisia, Venezuela were the planned locations as per European Clinical Trials Database record.
- 21 Mar 2018 Status changed from recruiting to completed.